Summary Little is known regarding the activity and function of the androgen receptor (AR) in human breast cancer. In the present study AR was evaluated in untreated primary breast cancers using antisera to the aminoand carboxy-termini of the receptor and quantitated using colour video image analysis. A 
Androgens regulate breast cancer cell proliferation in vitro via interaction with the androgen receptor (AR) (Truss and Beato, 1993) . However, divergent responses to androgens are seen in different human breast cancer cell lines. For example, androgens may stimulate (MCF-7, EFM-19, EVSA-T, MDA-MB-453) or inhibit (T-47D, ZR-75-1, MFM-223) the growth of AR-positive breast cancer cell lines in vitro (Birrell et al., 1995a; Hackenberg et al., 1988 Hackenberg et al., , 1991 Hall et al., 1994; Marugo et al., 1992; Poulin et al., 1988) . This divergent proliferative response to androgens may in part be due to alterations in the AR gene, resulting in altered receptor function and activation of androgen-regulated genes (Berger and Watson, 1989) , or interaction between AR and other steroid receptors [e.g. oestrogen receptor (ER) and progesterone receptor (PR)] differentially expressed in breast cancer cells.
Sensitive immunostaining techniques indicate that up to 80% of human breast tumours are AR-positive (Isola, 1993; Kuenen-Boumeester et al., 1992) and, perhaps more importantly, 25% of breast tumour metastases express AR when ER and PR levels are undetectable (Lea et al., 1989) . Although androgens are not routinely used in the treatment of human breast cancer owing to the unacceptable side-effects of treatment, indirect clinical evidence suggests that the AR may be an important mediator of hormonal therapy in breast tumours in vivo (Bryan et al., 1984) . We recently reported that the level of AR expression in primary breast cancers was the sole predictor of response to medroxyprogesterone acetate (MPA) administered following relapse on tamoxifen therapy (Birrell et al., 1995b) . MPA, a synthetic progestin widely used in the treatment of metastatic breast cancer, binds to the AR with high affinity (S Birrell and WD Tilley, unpublished results). Thus, the clinical and in vitro findings suggest that the. anti-tumour activity and/or androgenic sideeffects observed in women treated with MPA may be mediated in part by the AR.
Previous studies in our laboratory using computerised colour video image analysis (VIA) to compare prostate cancers stained with antisera directed against the amino-and carboxy-termini of the AR, identified a subgroup of tumours with discordant staining between the two AR antisera . It was proposed that the differences in AR staining observed with the two antisera might be due to structural alterations in the receptor. This has subsequently been confirmed by analysis of the AR gene sequence in the same group of prostate cancer patients (Tilley et al., 1996) . In contrast, prostate specimens derived from patients with benign disease exhibited concordant immunostaining with the amino-and carboxy-terminal AR antisera and amino acid substitutions in the AR were detected in only a single specimen (Tilley et al., 1996) . These studies demonstrate the use of immunohistochemical techniques to examine the structure of AR in tissue specimens.
AR function or mutations in the AR gene have not been extensively investigated in human breast cancers. The development of breast cancer in three men has been linked to inherited mutations in the DNA-binding domain of the AR (Lobaccaro et al., 1993; Wooster et al., 1992) , while in a recent report it was demonstrated that the human breast cancer cell lines, MCF-7 and T-47D, contain a splice variant of AR missing exon 3 (Zhu et al., 1996) , is a glycoprotein present in high concentrations in human breast gross cystic disease fluid (Balbin et al., 1990) . Apo-D is also expressed in breast cancers and the cellular levels of apo-D may be used to predict disease-free interval and overall survival (Diez-Itza et al., 1994 Simard et al., 1992) , retinoic acid (Lopez-Boado et al., 1994) and the cytokine, interleukin la (Blais et al., 1994 (Lambert et al., 1993) . Although the biological function of tissue apo-D is unknown, the androgen regulation of apo-D and the high-affinity binding of progesterone and pregnenolone to apo-D (Lea et al., 1987) , suggest that it may be involved in tissue metabolism and/or processing of steroids.
In order to define AR structure and activity in breast cancer better, primary breast tumours were stained using amino-and carboxy-terminal AR antibodies and the staining intensity and distribution evaluated using colour VIA. (Bloom and Richardson, 1957) . One specimen was ductal carcinoma in situ, seven tumours (19%) were grade I, i.e. well-differentiated carcinomas, 16 tumours (44%) were grade II and 12 tumours (33%) were grade III, i.e. poorly differentiated carcinomas. ER and PR content of the tumours was routinely determined by radioligand binding (Birrell et al., 1995b) and an additional portion of each tumour specimen was embedded in Tissue-Tek OCT compound (Miles Scientific, Naperville, IL, USA) and frozen at -70°C until processed.
Immunohistochemistry Sections (5,m) were cut from either frozen tissue or archival paraffin blocks and placed on poly-L-lysine (Sigma, St Louis, MO, USA)-coated slides. To retrieve AR antigenicity, paraffin sections were boiled in 10 mm citrate buffer (pH 6.5) in a microwave for 15 min (Loda et al., 1994) . Immunoperoxidase staining for AR was performed as previously described (Husmann et al., 1990; Tilley et al., 1994) using three affinity-purified rabbit anti-peptide antibodies that recognise epitopes in the amino terminus (amino acids 1-21, designated ARU402), the internal A domain (amino acids 200-220, designated ARU407) and the carboxy terminus (amino acids 898-917, designated ARR489) of the human AR (Zoppi et al., 1993) . The AR antisera 
Discussion
Although the role of the AR in breast tumorigenesis, growth of breast cancers and tumour responsiveness to endocrine therapies is poorly understood, the widespread expression of AR demonstrated in the present and previous studies (Isola, 1993; Kuenen-Boumeester et al., 1992; Lea et al., 1989) suggests that this pathway may be of biological and clinical importance in human breast cancer. In this study, AR immunoreactivity was evident in all of the breast tumours evaluated. Two recent immunohistochemical studies reported incidences of 76% (Kuenen-Boumeester et al., 1992) and 79% AR-positive breast tumours (Isola, 1993) . The lower levels of AR expression reported in these studies may have been due to decreased sensitivity of the monoclonal antibody employed (F39.4) as compared with polyclonal antisera ARU402 and ARR489, and the use in these studies of arbitrary cut-offs for AR positivity of 10% (Kuenen-Boumeester et al., 1992) or 20% AR-positive cells (Isola, 1993) . In addition, the use of VIA in the present study has permitted analysis of a larger proportion of the tumour specimen and more sensitive detection of breast cancers expressing low levels of AR. Of interest was the similar finding of the current study and that of Kuenen-Boumeester et al. (1992) , which reported that the intensity of AR immunoreactivity in breast cancer cells was directly proportional to the percentage of AR-positive nuclei. These observations are in contrast to that seen in human prostate cancers and Tilley, unpublished results) and suggest altered regulation of AR expression and/ or stability in breast cancer. AR immunoreactivity was localised to the nuclei of tumour cells and no stromal staining was observed. Stromal AR positivity has been reported in a single study in nonmalignant breast specimens (Kimura et al., 1993) . However, the studies of Kuenen-Boumeester et al. (1992) and Isola (1993) report negative staining for AR in breast cancerassociated stromal cells. While ER and PR are also localised in the nucleus of malignant and non-malignant breast epithelial cells and are not present in the stroma (Isola, 1993; Kuenen-Boumeester et al., 1992) , AR, ER and PR are detected in both epithelial and stromal cells of the prostate (Brolin et al., 1992; Husmann et al., 1990) . The functional significances of the localisation of these receptors in relation to the biological actions of the steroid ligands in breast and prostate is unknown. However, since the AR, ER and PR are absent from breast stroma. paracrine factors are unlikely to mediate steroid effects in breast cancer. as they do in the prostate (Steiner. 1995) .
We have previously demonstrated that differential staining with antisera that bind to epitopes in the amino-and carboxy-termini of the AR may be used to detect prostate cancer specimens contaimng amino acid substitutions in the AR (Tilley et al.. 1996) . The finding of ten breast tumour specimens with discordant staining between the amino-and carboxy-termini of the AR is similarly suggestive of structural alterations in the AR protein complex. Recently. a novel 87 kDa isoform of the AR was reported in human genital skin fibroblasts (Wilson and McPhaul. 1994) . The distnrbution of this AR isoform in other human tissues and its functional activity have not yet been characterised. Decreased AR immunostaining at the amino-terminus of the receptor in individual breast tumour specimens may therefore also indicate the presence of amino-terminal truncated variants of AR. in addition to AR gene mutations that result in amino acid substitutions. However. it is unlikely that the 87 kDa isoform contributes to the discordance in immnunoreactivity at the amino-and carboxy-termini of the AR in the present study, since nine of these ten tumours also showed discordant staining between AR antisera directed against an internal AR epitope. which recognises the 87 kDa AR isoform and the carboxy-terminal AR antisera. Further cDNA sequence analysis of AR will confirm the presence of mutations and or alternative AR isoforms in these breast cancer specimens.
Increased expression of apo-D in breast cancers has been associated previously with longer relapse-free and overall survival (Diez-Itza et al.. 1994) . In that study. expression of apo-D was not found to be related to ER or staining for the oestrogen-responsive gene. pS2. Although apo-D regulation by androgens is evident in breast cancer cell lines in vitro : Simard et al.. 1992 . the lack of correlation between AR and apo-D immunostaining in breast cancer cells and tumour tissues in vivo suggests that factors other than AR regulate cellular apo-D levels in breast cancers. Whereas progestins. glucocorticoids. retinoids and interleukin lx have been shown to regulate apo-D levels in vitro (Blais et al.. 1994 : Lambert et al.. 1993 : Lopez-Boado et al.. 1994 . the association of such factors with cellular levels of apo-D in breast tumour cells is unknown. These determinants. or the presence of apo-D itself. however. may confer the observed prognostic advantage to patients with breast cancers expressing increased levels of apo-D.
The findings in the present study of a wide range of AR immunopositivity in primary breast tumours and the previous correlation of AR levels and response to hormonal (MPA) therapy (Birrell et al.. 1995b) 
